July 13, 2016 | Israeli molecular diagnostic company ImmunArray has closed a Series B financing round of $10 million led by private investment firm Exigent. With offices in Rehovot, Israel and Richmond, Virginia, ImmunArray has developed novel blood tests and pioneers new and more accurate ways to diagnose autoimmune diseases such as lupus as well as traumatic brain injury (TBI). The company was founded in 2006 based on iCHIP technology licensed from the Weizmann Institute of Science. iCHIP technology can determine the presence of a specific set of molecular biomarkers that are linked to particular disease or condition.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments